BACKGROUND: We examined (a) the expression of the antioxidative factor glutathione peroxidase (GPx) and the transcription factor nuclear factor E2-related factor 2 (Nrf2) following low-dose X-irradiation in endothelial cells (ECs) and (b) the impact of reactive oxygen species (ROS) and Nrf2 on functional properties of ECs to gain further knowledge about the anti-inflammatory mode of action of low doses of ionizing radiation. MATERIAL AND METHODS: EA.hy926 ECs and primary human dermal microvascular ECs (HMVEC) were stimulated by tumor necrosis factor-α (TNF-α, 20 ng/ml) 4 h before irradiation with single doses ranging from 0.3 to 3 Gy. The expression and activity of GPx and Nrf2 were analyzed by flow cytometry, colorimetric assays, and real-time PCR. The impact of ROS and Nrf2 on peripheral blood mononuclear cell (PBMC) adhesion was assayed in the presence of the ROS scavenger N-acetyl-L-cysteine (NAC) and Nrf2 activator AI-1. RESULTS: Following a low-dose exposure, we observed in EA.hy926 EC and HMVECs a discontinuous expression and enzymatic activity of GPx concomitant with a lowered expression and DNA binding activity of Nrf2 that was most pronounced at a dose of 0.5 Gy. Scavenging of ROS by NAC and activation of Nrf2 by AI-1 significantly diminished a lowered adhesion of PBMC to EC at a dose of 0.5 Gy. CONCLUSION: Low-dose irradiation resulted in a nonlinear expression and activity of major compounds of the antioxidative system that might contribute to anti-inflammatory effects in stimulated ECs.
BACKGROUND: We examined (a) the expression of the antioxidative factor glutathione peroxidase (GPx) and the transcription factor nuclear factor E2-related factor 2 (Nrf2) following low-dose X-irradiation in endothelial cells (ECs) and (b) the impact of reactive oxygen species (ROS) and Nrf2 on functional properties of ECs to gain further knowledge about the anti-inflammatory mode of action of low doses of ionizing radiation. MATERIAL AND METHODS: EA.hy926 ECs and primary human dermal microvascular ECs (HMVEC) were stimulated by tumor necrosis factor-α (TNF-α, 20 ng/ml) 4 h before irradiation with single doses ranging from 0.3 to 3 Gy. The expression and activity of GPx and Nrf2 were analyzed by flow cytometry, colorimetric assays, and real-time PCR. The impact of ROS and Nrf2 on peripheral blood mononuclear cell (PBMC) adhesion was assayed in the presence of the ROS scavenger N-acetyl-L-cysteine (NAC) and Nrf2 activator AI-1. RESULTS: Following a low-dose exposure, we observed in EA.hy926 EC and HMVECs a discontinuous expression and enzymatic activity of GPx concomitant with a lowered expression and DNA binding activity of Nrf2 that was most pronounced at a dose of 0.5 Gy. Scavenging of ROS by NAC and activation of Nrf2 by AI-1 significantly diminished a lowered adhesion of PBMC to EC at a dose of 0.5 Gy. CONCLUSION: Low-dose irradiation resulted in a nonlinear expression and activity of major compounds of the antioxidative system that might contribute to anti-inflammatory effects in stimulated ECs.
Authors: Benjamin Prokein; Henrik Holtmann; Matthias G Hautmann; Hans-Peter Rösler; Stefan Graeber; Yvonne Dzierma; Christian Ruebe; Jochen Fleckenstein; Marcus Niewald Journal: Strahlenther Onkol Date: 2017-02-27 Impact factor: 3.621
Authors: Michael Rückert; Lisa Deloch; Rainer Fietkau; Benjamin Frey; Markus Hecht; Udo S Gaipl Journal: Strahlenther Onkol Date: 2018-03-02 Impact factor: 3.621
Authors: Miriam Kullmann; Paul F Rühle; Alexandra Harrer; Anna Donaubauer; Ina Becker; Renate Sieber; Gerhart Klein; Claudia Fournier; Rainer Fietkau; Udo S Gaipl; Benjamin Frey Journal: Radiat Environ Biophys Date: 2018-11-19 Impact factor: 1.925
Authors: Nadine Erbeldinger; Felicitas Rapp; Svetlana Ktitareva; Philipp Wendel; Anna S Bothe; Till Dettmering; Marco Durante; Thomas Friedrich; Bianca Bertulat; Stephanie Meyer; M C Cardoso; Stephanie Hehlgans; Franz Rödel; Claudia Fournier Journal: Front Immunol Date: 2017-06-01 Impact factor: 7.561
Authors: Christine E Hellweg; Luis F Spitta; Bernd Henschenmacher; Sebastian Diegeler; Christa Baumstark-Khan Journal: Front Oncol Date: 2016-03-21 Impact factor: 6.244